← Back to Investors

SV Health Investors

SV Health Investors is a leading transatlantic healthcare investment firm with offices in Boston and London. The firm invests across therapeutics, medical devices, diagnostics, and digital health, with a strong track record of backing companies that have achieved successful exits through IPOs and acquisitions.

Location
Boston, Massachusetts, USA & London, UK
Founded
1993
AUM
$2.5B+
Investment Range
$5M - $50M
Focus
biotech-focused
Fund Stages
seed, series-a, series-b, series-c, growth

Investment Thesis

SV Health Investors backs exceptional entrepreneurs building transformative healthcare companies. They invest across the healthcare spectrum from early-stage to growth, with deep expertise in life sciences, medical technology, and digital health. Their transatlantic presence provides portfolio companies with access to capital, talent, and partners on both sides of the Atlantic.

Team

Partners / Managing Directors

  • Kate Bingham, DBE - Managing Partner (led UK COVID-19 Vaccine Taskforce)
  • Houman Ashrafian, MD, PhD - Managing Partner
  • Michael Ross, MD, PhD - Managing Partner
  • Jean-Marc Guyot - Partner

Other Key Team Members

  • Cormac Sheridan - Partner
  • Adrian Rawcliffe - Partner

Focus Areas

  • Therapeutics (Oncology, Immunology, Neuroscience)
  • Medical Devices
  • Diagnostics
  • Digital Health
  • Gene & Cell Therapy
  • Drug Delivery

Notable Portfolio Companies

  • Oxford Nanopore - DNA sequencing technology (IPO 2021)
  • Bicycle Therapeutics - Bicyclic peptides (IPO 2019)
  • Achilles Therapeutics - Cancer immunotherapy (IPO 2021)
  • Mission Therapeutics - DUB inhibitors
  • Centessa Pharmaceuticals - Biotech platform (IPO 2021)

Notable Exits

  • Oxford Nanopore - IPO (2021, LSE: ONT)
  • Bicycle Therapeutics - IPO (2019, NASDAQ: BCYC)
  • Achilles Therapeutics - IPO (2021, NASDAQ: ACHL)
  • Centessa Pharmaceuticals - IPO (2021, NASDAQ: CNTA)
  • GW Pharmaceuticals - Acquired (2021, acquired by Jazz for $7.2B)
  • Adaptimmune - IPO (NASDAQ: ADAP)

Sources